JCAR017

Phase 2Small molecule

Bristol-Myers Squibb

JCAR017 is one of 44 small molecule programs targeting Lymphoma. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

LymphomaActive, not recruiting

Leukemia, Lymphocytic, Chronic, B-CellActive, not recruiting

LymphomaPhase 2

Active, not recruiting

Leukemia, Lymphocytic, Chronic, B-CellPreclinical

Active, not recruiting

Competition

Competitive Landscape

370 competitors in Lymphoma

#DrugCompanyPhaseTrials

Zofran

Novartis

Preclinical

2 2

Norvir

AbbVie

Preclinical

1 3

JCAR017

Bristol-Myers Squibb

Phase 2

3 4

Emend

CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Preclinical

1 5

Kenalog

BBausch Health Americas, Inc.

Preclinical

1 6

Nuvigil

NNuvo Research GmbH

Preclinical

1 7

Elitek

AAzienda U.S.L. 1 di Massa e Carrara

Preclinical

—8

Decadron

QQuince Therapeutics S.p.A.

Preclinical

—9

Solu-Medrol

MMassachusetts Eye and Ear Infirmary

Systemic Therapy

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2027

PreclinicalActive, not recruiting

Leukemia, Lymphocytic, Chronic, B-Cell

NCT03331198

Q3 2031

Phase 2Active, not recruiting

Lymphoma

NCT04245839

Clinical

Trials by Indication[1]

Lymphoma3 trials

Study Evaluating the Safety and Pharmacokinetics of JCAR017 in B-cell Non-Hodgkin Lymphoma (TRANSCEND-NHL-001)

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 1·NCT02631044·387 enrolled

A Study to Evaluate the Efficacy and Safety of JCAR017 in Adult Subjects With Relapsed or Refractory Indolent B-cell Non-Hodgkin Lymphoma (NHL)

Active, not recruiting· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 2·NCT04245839·276 enrolled

Trial to Determine the Efficacy and Safety of JCAR017 in Adult Participants With Aggressive B-Cell Non-Hodgkin Lymphoma

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 2·NCT03484702·113 enrolled

B-cell acute lymphoblastic leukemia1 trial

A Study to Evaluate the Safety and Efficacy of JCAR017 in Pediatric Subjects With Relapsed/Refractory (r/r) B-cell Acute Lymphoblastic Leukemia (B-ALL) and B-cell Non-Hodgkin Lymphoma (B-NHL)

Terminated· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 1/2·NCT03743246·21 enrolled

Relapsed/Refractory B-cell Malignancies1 trial

A Safety and Efficacy Trial of JCAR017 Combinations in Subjects With Relapsed/Refractory B-cell Malignancies

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 1/2·NCT03310619·62 enrolled

Leukemia, Lymphocytic, Chronic, B-Cell1 trial

An Open-Label, Phase 1/2 Study of JCAR017 in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma (017004)

Active, not recruiting· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Preclinical·NCT03331198·320 enrolled

Sources

References

[1]
ClinicalTrials.gov — 6 trial records for JCAR017. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — JCAR017 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for JCAR017. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Bristol-Myers Squibb company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: Bristol-Myers Squibb

JCAR017

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2027

Q3 2031

Trials by Indication[1]

Lymphoma3 trials

B-cell acute lymphoblastic leukemia1 trial

Relapsed/Refractory B-cell Malignancies1 trial

Leukemia, Lymphocytic, Chronic, B-Cell1 trial

References

Drug Info

Quick Facts

Related News